trending Market Intelligence /marketintelligence/en/news-insights/trending/tjjlhetd66qrs8ppwyujqg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Bristol-Myers Squibb, Calithera enter clinical collaboration for cancer drug

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Bristol-Myers Squibb, Calithera enter clinical collaboration for cancer drug

Calithera BioSciences Inc. is partnering with Bristol-Myers Squibb Co. to determine whether its CB-839 drug can be combined with Opdivo to treat kidney cancer.

Bristol-Myers' Opdivo is already approved as a treatment for certain types of cancer. CB-839 is currently in phase 1/2 clinical studies involving patients with clear cell renal cell carcinoma.